Academic literature on the topic 'Transparent testing guidelines'

Language testing and assessment have moved center stage in recent years, whether for educational, employment, or sociopolitical reasons. More and more people are involved in developing tests and using test score outcomes, though often without a background or training in assessment to equip them adequately for this role. Simultaneously, increasing professionalization of the field has led to the generation of standards, ethical codes, and guidelines for good testing practice. Although these can help make assessment practices more transparent and accessible to a wider constituency, they also risk promoting a view of language testing as highly technical and specialized–best left to experts. These trends have implications for both policy and practice. This article reviews efforts to promote understanding of assessment within the field of applied linguistics and within education and society more broadly. The role of professional associations, academic institutions, and commercial organizations in developing assessment literacy is considered, as well as the contribution of published material and other types of training resources. This article reflects on how the international language testing community can encourage the sharing of the core knowledge, skills, and understanding that underpin good quality assessment as widely and accessibly for the benefit of all.

17000 Background: In the last decade, the Program in Evidence-based Care (PEBC), the guideline initiative of the cancer system in Ontario, Canada, has evolved dramatically. In addition to providing recommendations to facilitate decisions of clinicians (clinical practice guidelines), PEBC reports provide recommendations to facilitate decisions regarding universal drug funding, resource allocation, models of care, and the organization of the cancer system. For many of these issues, there is little in terms of traditional evidence, regardless of study design. As such, extending and building upon traditional notions of evidence and methodologies to gather new kinds of evidence have been required. Methods and Results: The PEBC has evolved the way it which conceives of evidence, the methods used to assemble and appraise evidence, and the role of evidence in decision making. To this end, environmental scan and consensus methods, in addition to standard systematic review methodology, are employed. The environmental scan methodology we use includes systematic and transparent internet searches of, and/or direct inquires to, organizations in jurisdictions determined, a priori, to be generalizable to the Ontario experience. Here, evidence comes in the form of organizational reports, case studies and evaluation data. These methods continue to be refined and tested. The consensus methodology we use is a modified Delphi technique. To date, these methods have been applied to various topics including standards for diagnostic assessment programs, surgical oncology and systemic therapy models of care, patient education, multidisciplinary case conferences, patient safety, and treatment of rare diseases. Evaluations of these reports have been generally positive (approval rating range: 56% to 75%) but noticeably more varied than approval ratings of our clinical practice guidelines that have relied primarily on traditional systematic review methodology (approval ratings rarely below 80%). Conclusions: The PEBC's notions of evidence continue to evolve as does the refinement and testing of new methodologies. Through this evolution, we are now able to provide advice on issues we would otherwise be unable to using traditional methods only, while still remaining true to our core principles of being participatory, rigorous, systematic and transparent. No significant financial relationships to disclose.

The synergies between remote sensing technologies and ecological research have opened new avenues for the study of alien plant invasions worldwide. Such scientific advances have greatly improved our capacity to issue warnings, develop early-response systems and assess the impacts of alien plant invasions on biodiversity and ecosystem functioning. Hitherto, practical applications of remote sensing approaches to support nature conservation actions are lagging far behind scientific advances. Yet, for some of these technologies, knowledge transfer is difficult due to the complexity of the different data handling procedures and the huge amounts of data it involves per spatial unit. In this context, the next logical step is to develop clear guidelines for the application of remote sensing data to monitor and assess the impacts of alien plant invasions, that enable scientists, landscape managers and policy makers to fully exploit the tools which are currently available. It is desirable to have such guidelines accompanied by freely available remote sensing data and generated in a free and open source environment that increases the availability and affordability of these new technologies. Here we present a toolbox that provides an easy-to-use, flexible, transparent and open source set of tools to sample, map, model and assess the impact of alien plant invasions using two high-resolution remote sensing products (hyperspectral and LiDAR images). This online toolbox includes a real case dataset designed to facilitate testing and training in any computer system and processing capacity.

Introduction: A novel coronavirus SARS-CoV-2 RNA, detected by reverse-transcription polymerase chain reaction (RT-PCR) was identified as the cause of a cluster of pneumonia cases in Wuhan, China. It rapidly spread, at first in China, then resulting in an epidemic in other countries throughout the world. One of such controversial topics is the issue of diagnostics and interpretation of test for COVID-19. According to Polish and global guidelines, the basis for diagnosis is molecular testing – real-time reverse transcriptasepolymerase chain reaction (RT-PCR). Taking all these data into consideration, the aim of the study was to compare RT-PCR with serological test in our employees post-exposure. According to Polish and global guidelines, the basis for diagnosis is molecular testing, real-time reverse transcriptase-polymerase chain reaction (RT-PCR). The aim: To compare RT-PCR with serological test in our employees post-exposure. Material and methods: 79 employees of the Clinic, 19 men and 60 women in the age range 27-69 years were evaluated. Tests were begun four days after information about the positive test in our „Employee 0” and lasted for 7 days. At first, we made RT-PCR tests on the specimen from nasopharyngeal swab. Then, we accomplished rapid antibodies tests. This test is based on the qualitative assessment of the presence of IgM and IgG antibodies by immunochromatography using a sample of capillary blood from the fingertip. Results: All the tests were negative. No employee developed symptoms during the 7-day follow-up after the end of the tests. Conclusions: As routine tests for patients have been implemented widely, but similar solutions for employees have not gained popularity. Use of personal protective equipment (PPE) e.g. facemask and shields, transparent screens, disposable medical uniforms, minimalization the contact time, increasing distance from both colleagues and patients (if possible), and strictly follow sanitary procedures largely contributed to the absence of illness in the surveyed group of employees.

At the beginning of the coronavirus disease-19 pandemic, health care staff at a level 1 trauma center in the state of New York experienced facial irritation and skin breakdown under their N95 respirators due to increased and prolonged use. PURPOSE: Members of the Certified Wound and Ostomy Nurse, Nurse Practitioners staff were charged with developing recommendations within 48 hours to help prevent and manage facial skin issues using available products that would not compromise the seal of the respirators. METHOD: With the assistance of a health care safety specialist from the Environmental Health and Safety Department of the hospital, an ambient particle counting device was used to measure the N95 fit factor following application of a liquid skin barrier, transparent film dressing, light silicone-based adhesive dressing, or an extra-thin hydrocolloid dressing on the bridge of the nose and the cheekbones underneath an N95 respirator of 2 hospital staff members who volunteered to test the dressings. RESULTS: All thin dressings tested showed a fit factor over 100, reflecting an effective seal. The highest fit factors were seen with the liquid skin barrier in the 2 volunteers (200 and 198, respectively). Thin dressing usage information was included in the hospital guidelines for N95 respirators and shared with staff. Subsequent feedback suggests that the light silicone-based adhesive dressing and the extra-thin hydrocolloid dressing were preferred. CONCLUSION: Thin dressing use may help reduce skin complications among hospital staff during periods of extended N95 respirator wear time. Because use of the dressings did not result in failure of the quantitative fit test, they were permitted for use by health care staff under their N95 respirators. Studies are needed to help health care facilities optimize N95 respirator use to protect staff from coronavirus disease-19 and respirator-related skin complications while supply shortages remain.

Contemporary theory of argumentation offers many insights about the ways in which, in the context of a public controversy, arguers should ideally present their arguments and criticize those of their opponents. We also know that in practice not all works out according to the ideal patterns: numerous kinds of derailments (fallacies) are an object of study for argumentation theorists. But how about the use of unfair strategies vis-à-vis one’s opponents? What if it is not a matter of occasional derailments but of one party’s systematic refusal to take other parties seriously? What if one party continually forgoes any form of critical testing and instead resorts to threats or blackmail? Can this be countered by the tools of reason? Or should one pay one’s opponent back in the same coin? To gain some grasp of these issues, we describe a number of strategies used in the public controversy about induced earthquakes in Groningen. We check whether these strategies are fair, i.e. balanced, transparent, and tolerant. We also investigate the effects of the choice for a particular kind of strategy. It appears that, in circumstances, choosing a fair strategy may be detrimental for resolving the controversy and choosing an unfair one beneficial. Following up ideas from social psychology and political science, we formulate some guidelines for the choice of strategies. At the end, we stress the importance — especially for those whose opinions carry little weight — of having a society in which the knowledge and skills needed for assessing the fairness of strategies are widespread.

Dose articulation is a universal issue of intervention development and testing. In stroke recovery, dose of a nonpharmaceutical intervention appears to influence outcome but is often poorly reported. The challenges of articulating dose in nonpharmacological stroke recovery research include: (1) the absence of specific internationally agreed dose reporting guidelines; (2) inadequate conceptualization of dose, which is multidimensional; and (3) unclear and inconsistent terminology that incorporates the multiple dose dimensions. To address these challenges, we need a well-conceptualized and consistent approach to dose articulation that can be applied across stroke recovery domains to stimulate critical thinking about dose during intervention development, as well as promote reporting of planned intervention dose versus actually delivered dose. We followed the Design Research Paradigm to develop a framework that guides how to articulate dose, conceptualizes the multidimensional nature and systemic linkages between dose dimensions, and provides reference terminology for the field. Our framework recognizes that dose is multidimensional and comprised of a duration of days that contain individual sessions and episodes that can be active (time on task) or inactive (time off task), and each individual episode can be made up of information about length, intensity, and difficulty. Clinical utility of this framework was demonstrated via hypothetical application to preclinical and clinical domains of stroke recovery. The suitability of the framework to address dose articulation challenges was confirmed with an international expert advisory group. This novel framework provides a pathway for better articulation of nonpharmacological dose that will enable transparent and accurate description, implementation, monitoring, and reporting, in stroke recovery research.

Objective: The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPG). Methods: Recommendations are based on diligent reviews of clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols. Results: The Executive Summary of this 2019 updated guideline contains 58 numbered recommendations: 12 are Grade A (21%), 19 are Grade B (33%), 21 are Grade C (36%), and 6 are Grade D (10%). These detailed, evidence-based recommendations allow for nuance-based clinical decision-making that addresses multiple aspects of real-world care of patients. The evidence base presented in the subsequent Appendix provides relevant supporting information for the Executive Summary recommendations. This update contains 357 citations of which 51 (14%) are evidence level (EL) 1 (strong), 168 (47%) are EL 2 (intermediate), 61 (17%) are EL 3 (weak), and 77 (22%) are EL 4 (no clinical evidence). Conclusion: This CPG is a practical tool that practicing endocrinologists and regulatory bodies can refer to regarding the identification, diagnosis, and treatment of adults and patients transitioning from pediatric to adult-care services with growth hormone deficiency (GHD). It provides guidelines on assessment, screening, diagnostic testing, and treatment recommendations for a range of individuals with various causes of adult GHD. The recommendations emphasize the importance of considering testing patients with a reasonable level of clinical suspicion of GHD using appropriate growth hormone (GH) cut-points for various GH–stimulation tests to accurately diagnose adult GHD, and to exercise caution interpreting serum GH and insulin-like growth factor-1 (IGF-1) levels, as various GH and IGF-1 assays are used to support treatment decisions. The intention to treat often requires sound clinical judgment and careful assessment of the benefits and risks specific to each individual patient. Unapproved uses of GH, long-term safety, and the current status of long-acting GH preparations are also discussed in this document. LAY ABSTRACT This updated guideline provides evidence-based recommendations regarding the identification, screening, assessment, diagnosis, and treatment for a range of individuals with various causes of adult growth-hormone deficiency (GHD) and patients with childhood-onset GHD transitioning to adult care. The update summarizes the most current knowledge about the accuracy of available GH–stimulation tests, safety of recombinant human GH (rhGH) replacement, unapproved uses of rhGH related to sports and aging, and new developments such as long-acting GH preparations that use a variety of technologies to prolong GH action. Recommendations offer a framework for physicians to manage patients with GHD effectively during transition to adult care and adulthood. Establishing a correct diagnosis is essential before consideration of replacement therapy with rhGH. Since the diagnosis of GHD in adults can be challenging, GH–stimulation tests are recommended based on individual patient circumstances and use of appropriate GH cut-points. Available GH–stimulation tests are discussed regarding variability, accuracy, reproducibility, safety, and contraindications, among other factors. The regimen for starting and maintaining rhGH treatment now uses individualized dose adjustments, which has improved effectiveness and reduced reported side effects, dependent on age, gender, body mass index, and various other individual characteristics. With careful dosing of rhGH replacement, many features of adult GHD are reversible and side effects of therapy can be minimized. Scientific studies have consistently shown rhGH therapy to be beneficial for adults with GHD, including improvements in body composition and quality of life, and have demonstrated the safety of short- and long-term rhGH replacement. Abbreviations: AACE = American Association of Clinical Endocrinologists; ACE = American College of Endocrinology; AHSG = alpha-2-HS-glycoprotein; AO-GHD = adult-onset growth hormone deficiency; ARG = arginine; BEL = best evidence level; BMD = bone mineral density; BMI = body mass index; CI = confidence interval; CO-GHD = childhood-onset growth hormone deficiency; CPG = clinical practice guideline; CRP = C-reactive protein; DM = diabetes mellitus; DXA = dual-energy X-ray absorptiometry; EL = evidence level; FDA = Food and Drug Administration; FD-GST = fixed-dose glucagon stimulation test; GeNeSIS = Genetics and Neuroendocrinology of Short Stature International Study; GH = growth hormone; GHD = growth hormone deficiency; GHRH = growth hormone–releasing hormone; GST = glucagon stimulation test; HDL = high-density lipoprotein; HypoCCS = Hypopituitary Control and Complications Study; IGF-1 = insulin-like growth factor-1; IGFBP = insulin-like growth factor–binding protein; IGHD = isolated growth hormone deficiency; ITT = insulin tolerance test; KIMS = Kabi International Metabolic Surveillance; LAGH = long-acting growth hormone; LDL = low-density lipoprotein; LIF = leukemia inhibitory factor; MPHD = multiple pituitary hormone deficiencies; MRI = magnetic resonance imaging; P-III-NP = procollagen type-III amino-terminal pro-peptide; PHD = pituitary hormone deficiencies; QoL = quality of life; rhGH = recombinant human growth hormone; ROC = receiver operating characteristic; RR = relative risk; SAH = subarachnoid hemorrhage; SDS = standard deviation score; SIR = standardized incidence ratio; SN = secondary neoplasms; T3 = triiodothyronine; TBI = traumatic brain injury; VDBP = vitamin D-binding protein; WADA = World Anti-Doping Agency; WB-GST = weight-based glucagon stimulation test

Low rates of reproducibility and translatability of data from nonclinical research have been reported. Major causes of irreproducibility include oversights in study design, failure to characterize reagents and protocols, a lack of access to detailed methods and data, and an absence of universally accepted and applied standards and guidelines. Specific areas of concern include uncharacterized antibodies and cell lines, the use of inappropriate sampling and testing protocols, a lack of transparency and access to raw data, and deficiencies in the translatability of findings to the clinic from studies using animal models of disease. All stakeholders—academia, industry, funding agencies, regulators, nonprofit entities, and publishers—are encouraged to play active roles in addressing these challenges by formulating and promoting access to best practices and standard operating procedures and validating data collaboratively at each step of the biomedical research life cycle.

Abstract Preclinical hemolysis testing is a critical requirement toward demonstrating device safety for U.S. Food and Drug Administration (FDA) 510(k) approval of mechanical circulatory support devices (MCSD). FDA and ASTM (formerly known as the American Society for Testing and Materials) have published guidelines to assist industry with developing study protocols. However, there can be significant variability in experimental procedures, study design, and reporting of data that makes comparison of test and predicate devices a challenge. To overcome these limitations, we present a hemolysis testing protocol developed to enable standardization of hemolysis testing while adhering to FDA and ASTM guidelines. Static mock flow loops primed with fresh bovine blood (600 mL, Hematocrit = 27±5%, heparin titrated for ACT >300 sec) from a single-source donor were created as a platform for investigating test and predicate devices. MCSD differential pressure and temperature were maintained at 80 mmHg and 25°±2° C. Blood samples (3 ml) were collected at 0, 5, 90, 180, 270, 360 minutes to measure CBC and plasma free hemoglobin. This protocol led to 510(k) approval of two adult MCSD and has been used to test novel cannulae and a pediatric MCSD. Standardization of hemolysis testing procedures and transparency of results may enable better blood trauma characterization of MCS devices to facilitate the FDA 510(k) and PMA submission processes and improve clinical outcomes.

AbstractThis chapter examines whether the rules regarding Insurance Product Information Documents mandated in Article 20 of the Insurance Distribution Directive, have, in reality, resulted in policyholders being able to easily and transparently compare different offers in the pre-contractual phase to determine whether an insurance product is appropriate for the policyholder.The format of the Insurance Product Information Document has been determined following thorough analytical work (such as EIOPA’s Draft Implementing Technical Standards concerning a standardised presentation format for the Insurance Product Information Document of the Insurance Distribution Directive of 7 February 2017, EIOPA-17/056, including the related consumer testing and consultations.). However, there are no guidelines or rules for insurers to follow when completing the Insurance Product Information Document. Based on an examination of selected insurance products from various insurers, this chapter concludes that there is a significant discrepancy between how different insurers complete the Insurance Product Information Documents. Such discrepancy occurs even when the cover offered by the insurers is identical or almost identical. This chapter discusses whether this is expedient and whether there is a need to draw up guidelines or rules on the completion of the Insurance Product Information Document in order to provide instructions to the insurers and to allow customers to make informed comparisons of insurance products.On the whole, this chapter concludes that there is a need for at least guidelines, if not regulation, if the Insurance Product Information Document is to be an effective and useful basis for comparison in the pre-contractual phase.

Standards are part of our lives. Clinical costing is no exception in this regard. Clinical costing standards are published documents comprising specifications and procedures to build consistent datasets for statutory purposes. The Independent Hospital Pricing Authority publishes and updates Australian Hospital Patient Costing Standards. The standards ensure compatibility and credibility. The standards formulate a consistent and transparent way to process costing. Compliance represents the production of reliable information which could be compared locally, nationally, and internationally. Health professionals could utilize these standards-compliant datasets for testing clinical guidelines for patient safety, developing patient classification systems for counting clinical services, and setting national efficient price for public hospital funding. The ultimate goal is to improve healthcare delivery in an equitable way and reduce human suffering.

Abstract A special subset of pressures vessels are required to fully contain internal explosive blasts for commercial and government agencies conducting blast-related research and testing. In some cases these blast chambers must also safely contain the impact of high-speed fragments that may be created from cased munitions and devices. Both of these loading conditions require specific analysis methods, for example penetration mechanics and specialized dynamic finite element simulation. Careful attention must also be paid to the construction of these blast chambers, which typically utilize very thick steel plate, large forgings and pressings, and thorough weld procedure and inspection development. Beside the typical steel pressure vessel body, many ports are needed in such vessels, including those that house thick windows. These elements are typically the areas of highest stress concentration. Fatigue analysis is also conducted, using the predicted stress states, to ensure the pressure vessel will survive the required number of tests. Due to the potentially hazardous operation of the vessel, they must also undergo extensive post-construction proof testing to verify their safety and to validate the design/analysis approach. Methods to address the repetitive impulsive loading and fatigue failure are described in ASME BPVC Code Case 2564-5 Impulsively Loaded Pressure Vessels. An approach taken to satisfy those guidelines is described in this paper. Southwest Research Institute (SwRI) has designed, constructed, and tested many blast chambers in the last 30 years. This paper discusses the specialized work needed for this class of vessel, including dynamic finite element analysis that accounts for shock pressure and quasi-static pressure. To illustrate the different steps specific examples are provided for key areas such as entry doorways and the viewports. Evaluation of internal shielding and transparency materials that must withstand impact are described. Example proof test methods are described and data obtained during recent projects will be included to demonstrate results.